biotrack
@biotrack15
Followers
64
Following
242
Media
1
Statuses
348
Interested in Biotech investing. Neither a Pumper nor a Dumper. I may share on what I may care. If you own, you are on your own.
Joined February 2022
AXSM - Just a hunch, not facts based. I feel that AXSM maybe acquired by July 2026 for about $15B to $18B by either JNJ or LLY or ABBV.
0
0
0
VTGN - Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder - Study did not demonstrate statistically significant improvement on primary endpoint of reduction in anxiety as measured by SUDS scores
0
0
1
TERN - Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML. 64% MMR achievement by 24 weeks across all efficacy evaluable patients. 75% MMR achievement by 24 weeks in efficacy evaluable patients at doses >320mg; Encouraging safety
0
0
1
GPCR vs WVE - GPCR - small molecule, pipeline, mostly, obesity focused, on obesity - fat and muscle losses, some side effects; WVE - RNA based, broad pipeline, AATD, Obesity, HD, DMD, etc., on obesity - mostly fat reduction, no muscle losses, little or no side effects.
0
0
1
RZLT - Rezolute Files For Mixed Shelf Offering, Size Not Disclosed
0
0
0
MESO and FDA met in June 2025 and aligned on items for filing a BLA for REVASCOR regarding chemistry, manufacturing & controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval.
0
0
0
My focus is on their next cell therapy candidate for Heart issues like HLHS and HFeRF. June 2025 - FDA informed MESO following a Type B meeting that the totality of the trial results could support accelerated approval under the RMAT for end-stage HFrEF patients with LVAD
1
0
0
$MESO - If anyone is looking to invest in an early commercial stage company. It is a cell therapy company. Now approved for Pediatric aGVHD and they received J-Code from the United States Medicare & Medicaid Services. Please see the thread for more....
1
0
0
Maxim Group analyst Jason McCarthy maintains Rezolute ( RZLT ) with a Buy and raises the price target from $15 to $20. Guggenheim analyst Debjit Chattopadhyay reiterates Rezolute ( RZLT ) with a Buy and maintains $15 price target.
0
0
0
NKTR - BTIG Reiterates Buy on Nektar Therapeutics, Maintains $100 Price Target
0
1
0
NKTR - Nektar Therapeutics Announces New Data From Ongoing REZOLVE-AD Phase 2b Study Of Rezpegaldesleukin At 2025 EADV Congress. Study met primary and key secondary endpoints at week 16 in patients with moderate-to-severe atopic dermatitis. Pre-Market up 14%.
0
0
0
NKTR - today's +ve market reaction is due to NKTR's earlier published results on atomic dermatitis is better than Sanofi's results published today.
0
0
0
4 of 4 - A solution, even if temporary, will pave the way for something better.
0
0
0
3 of 4 This gives some hope, some determination to the patients yes, they may be, functional, they may be able to live longer than what they have been told. Please understand for hard problems there is no perfect solution.
0
0
0